Breaking News

Immunicon, BMS Enter Biomarker Research Pact

Immunicon Corp. has entered into a research services agreement with Bristol-Myers Squibb (BMS) involving protein and molecular targets associated with circulating tumor cells (CTCs).

Leon Terstappen, M.D., Ph.D., chief scientific officer of Immunicon said, “The list of pharmaceutical partners and biomarkers continues to expand. Our collaborations span across protein biomarkers, phosphoproteins and a variety of FISH assays to study gene amplification in a number of different carcinomas. We believe that our development work will advance the understanding of cancer biology as well as accelerate the time to market for promising new drugs.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters